Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe3O4 nanoparticles for targeted drug delivery

Zhengzou Fang,1 Xinyuan Li,2 Zeyan Xu,3 Fengyi Du,3 Wendi Wang,1 Ruihua Shi,4 Daqing Gao11Department of Pathogenic Microbiology and Immunology, Southeast University School of Medicine, Nanjing 210009, People’s Republic of China; 2Department of Clinical Laboratory, Huai’an Hospita...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fang Z, Li X, Xu Z, Du F, Wang W, Shi R, Gao D
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	target-delivery HA-MSNs nanocarrier receptor-mediated cancer therapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/6b6d14b822984df09440042686dbd8e3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6b6d14b822984df09440042686dbd8e3
record_format	dspace
spelling	oai:doaj.org-article:6b6d14b822984df09440042686dbd8e32021-12-02T06:18:00ZHyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe3O4 nanoparticles for targeted drug delivery1178-2013https://doaj.org/article/6b6d14b822984df09440042686dbd8e32019-07-01T00:00:00Zhttps://www.dovepress.com/hyaluronic-acid-modified-mesoporous-silica-coated-superparamagnetic-fe-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Zhengzou Fang,1 Xinyuan Li,2 Zeyan Xu,3 Fengyi Du,3 Wendi Wang,1 Ruihua Shi,4 Daqing Gao11Department of Pathogenic Microbiology and Immunology, Southeast University School of Medicine, Nanjing 210009, People’s Republic of China; 2Department of Clinical Laboratory, Huai’an Hospital Affiliated to Xuzhou Medical College and Huai’an Second Hospital, Huai’an, Jiangsu, People’s Republic of China; 3Department of Gastroenterology, Jiangsu University, School of Medicine, Zhenjiang 212013, People’s Republic of China; 4Department of Gastroenterology, Affiliated Zhongda Hospital, Southeast University, Nanjing 210009, People’s Republic of ChinaIntroduction: The targeted delivery of anti-cancer drugs to tumor tissue has been recognized as a promising strategy to increase their therapeutic efficacy and reduce side effects. Mesoporous silica-coated superparamagnetic Fe3O4 nanoparticles (NH2-MSNs), a kind of nanocarrier, can passively enter tumor tissues to enhance the permeability and retention of drugs. However, NH2-MSNs do not specifically bind to cancer cells. This drawback encouraged us to develop a more efficient nanocarrier for cancer therapy.Methods: Herein, we describe the development of an effective nanocarrier based on NH2-MSNs, which were modified with hyaluronic acid on their surface (HA-MSNs) and loaded with doxorubicin (DOX). We have successfully fabricated uniform spherical HA-MSNs nanocarriers. The targeting ability of this delivery system was evaluated through specific uptake by cells and IVIS imaging.Results: DOX-HA-MSNs nanocarriers displayed more dramatic cytotoxic activity against 4T1 breast cancer cells compared to GES-1 gastric mucosa cells. In vivo results revealed that once DOX-HA-MSNs nanocarriers are exposed to an external magnetic field, they could be rapidly attracted to the magnet and effectively cross the cytoplasmic membrane via CD44 receptor-mediated transcytosis. This allows them to access the cancer cell cytoplasm and release DOX based on changes in the physiological environment. Both in vitro and in vivo results demonstrated that the HA-MSNs nanocarriers provided better therapeutic efficacy.Conclusion: The HA-MSNs nanocarriers represent an effective new paradigm to treat cancers due to active targeting to the tumor cells. Moreover, the specific uptake by the tumor effectively protects normal tissues to reduce off-target side effects. The reported findings support further investigation of HA-MSNs for cancer therapy.Keywords: target-delivery, HA-MSNs, nanocarrier, receptor-mediated, cancer therapyFang ZLi XXu ZDu FWang WShi RGao DDove Medical Pressarticletarget-deliveryHA-MSNsnanocarrierreceptor-mediatedcancer therapyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 5785-5797 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	target-delivery HA-MSNs nanocarrier receptor-mediated cancer therapy Medicine (General) R5-920
spellingShingle	target-delivery HA-MSNs nanocarrier receptor-mediated cancer therapy Medicine (General) R5-920 Fang Z Li X Xu Z Du F Wang W Shi R Gao D Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe3O4 nanoparticles for targeted drug delivery
description	Zhengzou Fang,1 Xinyuan Li,2 Zeyan Xu,3 Fengyi Du,3 Wendi Wang,1 Ruihua Shi,4 Daqing Gao11Department of Pathogenic Microbiology and Immunology, Southeast University School of Medicine, Nanjing 210009, People’s Republic of China; 2Department of Clinical Laboratory, Huai’an Hospital Affiliated to Xuzhou Medical College and Huai’an Second Hospital, Huai’an, Jiangsu, People’s Republic of China; 3Department of Gastroenterology, Jiangsu University, School of Medicine, Zhenjiang 212013, People’s Republic of China; 4Department of Gastroenterology, Affiliated Zhongda Hospital, Southeast University, Nanjing 210009, People’s Republic of ChinaIntroduction: The targeted delivery of anti-cancer drugs to tumor tissue has been recognized as a promising strategy to increase their therapeutic efficacy and reduce side effects. Mesoporous silica-coated superparamagnetic Fe3O4 nanoparticles (NH2-MSNs), a kind of nanocarrier, can passively enter tumor tissues to enhance the permeability and retention of drugs. However, NH2-MSNs do not specifically bind to cancer cells. This drawback encouraged us to develop a more efficient nanocarrier for cancer therapy.Methods: Herein, we describe the development of an effective nanocarrier based on NH2-MSNs, which were modified with hyaluronic acid on their surface (HA-MSNs) and loaded with doxorubicin (DOX). We have successfully fabricated uniform spherical HA-MSNs nanocarriers. The targeting ability of this delivery system was evaluated through specific uptake by cells and IVIS imaging.Results: DOX-HA-MSNs nanocarriers displayed more dramatic cytotoxic activity against 4T1 breast cancer cells compared to GES-1 gastric mucosa cells. In vivo results revealed that once DOX-HA-MSNs nanocarriers are exposed to an external magnetic field, they could be rapidly attracted to the magnet and effectively cross the cytoplasmic membrane via CD44 receptor-mediated transcytosis. This allows them to access the cancer cell cytoplasm and release DOX based on changes in the physiological environment. Both in vitro and in vivo results demonstrated that the HA-MSNs nanocarriers provided better therapeutic efficacy.Conclusion: The HA-MSNs nanocarriers represent an effective new paradigm to treat cancers due to active targeting to the tumor cells. Moreover, the specific uptake by the tumor effectively protects normal tissues to reduce off-target side effects. The reported findings support further investigation of HA-MSNs for cancer therapy.Keywords: target-delivery, HA-MSNs, nanocarrier, receptor-mediated, cancer therapy
format	article
author	Fang Z Li X Xu Z Du F Wang W Shi R Gao D
author_facet	Fang Z Li X Xu Z Du F Wang W Shi R Gao D
author_sort	Fang Z
title	Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe3O4 nanoparticles for targeted drug delivery
title_short	Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe3O4 nanoparticles for targeted drug delivery
title_full	Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe3O4 nanoparticles for targeted drug delivery
title_fullStr	Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe3O4 nanoparticles for targeted drug delivery
title_full_unstemmed	Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe3O4 nanoparticles for targeted drug delivery
title_sort	hyaluronic acid-modified mesoporous silica-coated superparamagnetic fe3o4 nanoparticles for targeted drug delivery
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/6b6d14b822984df09440042686dbd8e3
work_keys_str_mv	AT fangz hyaluronicacidmodifiedmesoporoussilicacoatedsuperparamagneticfe3o4nanoparticlesfortargeteddrugdelivery AT lix hyaluronicacidmodifiedmesoporoussilicacoatedsuperparamagneticfe3o4nanoparticlesfortargeteddrugdelivery AT xuz hyaluronicacidmodifiedmesoporoussilicacoatedsuperparamagneticfe3o4nanoparticlesfortargeteddrugdelivery AT duf hyaluronicacidmodifiedmesoporoussilicacoatedsuperparamagneticfe3o4nanoparticlesfortargeteddrugdelivery AT wangw hyaluronicacidmodifiedmesoporoussilicacoatedsuperparamagneticfe3o4nanoparticlesfortargeteddrugdelivery AT shir hyaluronicacidmodifiedmesoporoussilicacoatedsuperparamagneticfe3o4nanoparticlesfortargeteddrugdelivery AT gaod hyaluronicacidmodifiedmesoporoussilicacoatedsuperparamagneticfe3o4nanoparticlesfortargeteddrugdelivery
_version_	1718399996677586944

Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe3O4 nanoparticles for targeted drug delivery

Ejemplares similares